Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Special issues
    • Subject collections
    • Cell Scientists to Watch
    • First Person
    • Sign up for alerts
  • About us
    • About JCS
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Fast-track manuscripts
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • JCS Prize
    • Manuscript transfer network
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contacts
    • Contact JCS
    • Subscriptions
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Journal of Cell Science
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Journal of Cell Science

  • Log in
Advanced search

RSS   Twitter  Facebook   YouTube  

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Special issues
    • Subject collections
    • Cell Scientists to Watch
    • First Person
    • Sign up for alerts
  • About us
    • About JCS
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Fast-track manuscripts
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • JCS Prize
    • Manuscript transfer network
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contacts
    • Contact JCS
    • Subscriptions
    • Advertising
    • Feedback
Research Article
Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells
Richard S. Beard, Jr, Ricci J. Haines, Kevin Y. Wu, Jason J. Reynolds, Stephanie M. Davis, John E. Elliott, Nikolay L. Malinin, Victor Chatterjee, Byeong J. Cha, Mack H. Wu, Sarah Y. Yuan
Journal of Cell Science 2014 127: 1840-1853; doi: 10.1242/jcs.144550
Richard S. Beard Jr
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricci J. Haines
2Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Y. Wu
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason J. Reynolds
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie M. Davis
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Elliott
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolay L. Malinin
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Chatterjee
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Byeong J. Cha
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mack H. Wu
2Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Y. Yuan
1Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: syuan@health.usf.edu
  • Article
  • Figures & tables
  • Supp info
  • Info & metrics
  • PDF + SI
  • PDF
Loading

Article Figures & Tables

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Diagram of signaling pathways through which non-muscle myosin light chain kinase (nmMlck) might be involved in IL-1β-mediated BMVEC barrier dysfunction. We hypothesize that nmMlck modulates IL-1β-mediated downregulation of Cldn5 and dysfunction of the BMVEC barrier in a manner that promotes the nuclear translocation of β-catenin and the repression of the Cldn5 gene. Question marks and dashed lines indicate unknown signaling mechanisms, whereas solid lines indicate previously established mechanisms.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Treating brain microvascular endothelial cells (bEnd.3 cells) with IL-1β induces a time- and dose-dependent decrease in TER while increasing size-selective monolayer permeability. (A) ECIS tracings of monolayers treated with vehicle control (0.1% BSA in PBS) or IL-1β (200 ng/ml). Tracings indicate the mean resistance normalized to t = 0 (indicated by arrow) and shading indicates s.e.m. (B) Statistical analysis of relative TER decline at the indicated time points during the treatment of bEnd.3 monolayers with IL-1β (either 100 or 200 ng/ml). (C) Time-course of the IL-1β-mediated increase in monolayer permeability to sodium fluorescein. (D) Monolayers were treated with vehicle control or IL-1β (100 ng/ml) for 24 hours, then transwell permeability assays were performed to determine permeability coefficients (PS) for the following molecules: sodium fluorescein (0.376 kDa; Stokes' radius≈0.45 nm), TRITC–dextran (4.4 kDa; Stokes' radius≈1.4 nm) and FITC–albumin (66.4 kDa; Stokes' radius≈3.48 nm). Data are presented as the mean±s.e.m. *P<0.05 compared with vehicle control or t = 0; one-way ANOVA with Dunnett's post hoc analysis.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    IL-1β decreases Cldn5 expression in bEnd.3 cells in a manner consistent with IL-1β-mediated barrier dysfunction. (A) Confocal immunofluorescence analysis of the tight junction proteins Cldn5 and zonula occludens-1 (ZO-1) after a 24-hour treatment with IL-1β (100 ng/ml), compared with vehicle control. Scale bars: 20 µm. Cldn5 and ZO-1 are colocalized at cell–cell contacts in vehicle-control-treated cells. In IL-1β-treated cells, no obvious expression or localization changes were observed for ZO-1; however, IL-1β induced a significant reduction in Cldn5 expression at cell–cell contacts. (B) Western blotting for Cldn5 in cell lysates demonstrated that treatment with IL-1β (100 ng/ml) induced ∼2-fold decrease in total Cldn5 protein expression. (C) ICWs were used to determine the time-course for the IL-1β-mediated decrease in Cldn5 protein expression. (D) Real-time PCR results demonstrate that IL-1β induced downregulation of Cldn5 mRNA that preceded the IL-1β-mediated decrease in Cldn5 protein expression. (E) Western blotting providing confirmation and quantification of Cldn5 knockdown that was obtained by treatment with targeted siRNA (siCldn5) or scrambled siRNA (siScr). (F) Permeability coefficients (PS) for sodium fluorescein, TRITC-dextran and FITC-albumin were measured in Cldn5-deficient BMVEC monolayers (siCldn5) with or without IL-1β (100 ng/ml) treatment for 24 hours, and were compared with those of siScr monolayers. Similar to IL-1β treatment, Cldn5 deficiency increased the permeability of the monolayer to sodium fluorescein and TRITC–dextran, but not to FITC–albumin. Moreover, treating Cldn5-deficient monolayers with IL-1β further increased the permeability of the monolayer to sodium fluorescein and TRITC–dextran, whereas FITC–albumin permeability remained unchanged. Data are presented as the mean±s.e.m. *P<0.05 compared with the vehicle control, the t = 0 time-point or siScr; #P<0.05 compared with siCldn5 alone; Student's t-test or one-way ANOVA with Dunnett's (C,D) and Tukey's (F) post hoc analysis.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    IL-1β treatment is associated with Akt inactivation, resulting in FoxO1 nuclear accumulation and FoxO1-dependent regulation of gene expression. (A) Representative western blots demonstrate that IL-1β (100 ng/ml for 1.5 hours) inactivated Akt, as indicated by a decrease in phosphorylation of T308. Consistent with inactivation of Akt, IL-1β treatment also led to decreased phosphorylation of FoxO1 on T24. (B) ICWs were used to quantify IL-1β-mediated dephosphorylation of Akt and FoxO1. (C) Western blot analysis of nuclear lysates demonstrated a significant increase in the nuclear accumulation of FoxO1 in response to IL-1β treatment. Lamin A/C was used as a loading control and Gapdh was used to determine the efficacy of nuclear fractionation. (D) Real-time PCR results showed upregulation of two known FoxO1 transcriptional targets, Cdkn1a and Pdk4. Data are presented as the mean±s.e.m. *P<0.05 compared with vehicle control; Student's t-test. (E) Confocal immunofluorescence analysis revealed an increased nuclear accumulation of FoxO1 in response to IL-1β treatment (c,d) compared with cells treated with vehicle control (a,b). Arrowheads represent the location of nuclei in images without nuclear staining. Scale bars: 20 µm.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Treatment of bEnd.3 cells with IL-1β leads to uncoupling of the VE-cadherin–β-catenin complex, an increase in the pool of active β-catenin, and nuclear localization of β-catenin. (A) Co-immunoprecipitation experiments demonstrated that there was a decrease in the amount of β-catenin (β-cat) that precipitated with VE-cadherin (VE-cad) after IL-1β treatment (100 ng/ml, 1.5 hours). (B) Western blotting for active β-catenin (clone 8E7) demonstrated an increase in active β-catenin immunolabeling after IL-1β treatment. Data represent the mean±s.e.m. (C) Western blot analysis of the nuclear fraction showed a significant increase in nuclear accumulation of β-catenin in response to IL-1β treatment. Lamin A/C was used as a loading control, and Gapdh was used to determine the efficacy of nuclear fractionation. The control blots showing Lamin A/C and Gapdh are duplicates of the controls shown in Fig. 4C, as these experiments were performed on the same nuclear extracts and western blots. (D) mRNA levels were determined for Cldn1, Cldn3, Cldn5, Cldn12, Ocln, Tjp1, Plvap and Axin2 from bEnd.3 cells that were treated with IL-1β. Data represent mean mRNA levels (±s.e.m.), shown as a percentage of vehicle control. *P<0.05 compared with vehicle control; Student's t-test. (E) Confocal immunocytochemistry demonstrates increased nuclear accumulation of β-catenin in response to IL-1β treatment (c without nuclei staining, d with nuclei staining) compared with vehicle control (a without nuclei staining, b with nuclei staining). Arrowheads represent the location of nuclei in images without nuclei staining. Scale bars: 20 µm.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    IL-1β requires the recruitment of FoxO1 and β-catenin to the Cldn5 repressor to reduce Cldn5 expression. 1.5 hours after treating bEnd.3 cells with IL-1β (100 ng/ml) or vehicle control, bound chromatin was immunoprecipitated (ChIP) with anti-FoxO1, anti-β-catenin or IgG isotype-control antibodies. ChIP samples were assayed by using PCR with primers for the putative Cldn5 repressor region, whereas primers for the Cldn5 coding sequence (CDS) were used as negative controls for non-specific DNA precipitation. (A,C) Qualitative PCR results from ChIP assays. (B,D) Quantitative RT-PCR results from ChIP assays. ΔCq (or percentage of total) for the Cldn5 repressor was calculated by normalizing to input. (E) Western blotting confirmation and quantification of gene knockdown using targeted siRNA against β-catenin (siβ-cat), FoxO1 (siFoxO1) or scrambled control (siScr). FoxO1 and β-catenin knockdown attenuated IL-1β-induced downregulation of Cldn5 mRNA at 1.5 hours after treatment (F) and barrier dysfunction at 24 hours (G). Data represent the mean±s.e.m. *P<0.05 compared with control, #P<0.05 compared with siScr treated with IL-1β; Student's t-test.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    nmMlck is required for β-catenin and FoxO1 occupancy of the Cldn5 repressor. Primary BMVECs were isolated from cortices of wild-type (nmmlck+/+) and nmMlck homozygous knockout (nmmlck−/−) mice. (A) Treating BMVECs with IL-1β (100 ng/ml) acutely (within 15 minutes) activated nmMlck, as indicated by increased phosphorylation of Y464 in a time-dependent manner. (B) ICWs were used to assess IL-1β-mediated inactivation of the Akt–FoxO1 pathway in BMVECs, by using phosphospecific antibodies against T308 on Akt (pT308 Akt) and T24 on FoxO1 (pT24 FoxO1). Antibodies against total Akt and FoxO1 were used for co-labeling, and the measurements were used to normalize phosphospecific signals. (C) IL-1β (100 ng/ml, 1.5 hours) increased the ratio of active β-catenin (hypophosphorylated at GSK3β sites Ser37 and Thr41) to total β-catenin in BMVECs isolated from nmmlck+/+ mice, but not in those isolated from nmmlck−/− mice. *P<0.05 compared with control. (D,E) Consistent with the inactivation and activation signals on Akt, FoxO1 and β-catenin, nmMlck deficiency attenuated IL-1β-mediated nuclear accumulation of β-catenin, but not nuclear accumulation of FoxO1. (F) Although IL-1β treatment led to nuclear accumulation of FoxO1 in both nmmlck+/+ and nmmlck−/− BMVECs, the absence of β-catenin in the nuclei of nmmlck−/− BMVECs treated with IL-1β prevented the binding of FoxO1 to the Cldn5 repressor. Data represent the mean±s.e.m. *P<0.05 compared with all other groups; Student's t-test.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    nmMlck deficiency attenuates IL-1β-mediated dysfunction of the brain endothelial barrier and Cldn5 downregulation. (A) Western blotting for Cldn5 in lysates from BMVECs treated with IL-1β (100 ng/ml, 24 hours) revealed that IL-1β-mediated Cldn5 downregulation is dependent on nmMlck. (B) ECIS experiments demonstrated that BMVECs from nmmlck+/+ mice respond to IL-1β in a similar fashion to bEnd.3 cells. (C) Ectopic expression of nmMlck in nmmlck−/− BMVECs reverts the attenuation of IL-1β-mediated barrier dysfunction. (D) Consistent with the evidence that activation of β-catenin is dependent on nmMlck, ectopic expression of active β-catenin in nmmlck−/− BMVECs also restores IL-1β-mediated barrier dysfunction. Data represent the mean±s.e.m. *P<0.05 compared with all other groups; Student's t-test.

Previous Article
Back to top
Previous Article

This Issue

Keywords

  • Non-muscle myosin light chain kinase
  • Claudin-5
  • Foxo1
  • IL-1β
  • β-catenin
  • Blood–brain barrier
  • Neuroinflammation

 Download PDF

Email

Thank you for your interest in spreading the word on Journal of Cell Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells
(Your Name) has sent you a message from Journal of Cell Science
(Your Name) thought you would like to see the Journal of Cell Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Research Article
Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells
Richard S. Beard, Jr, Ricci J. Haines, Kevin Y. Wu, Jason J. Reynolds, Stephanie M. Davis, John E. Elliott, Nikolay L. Malinin, Victor Chatterjee, Byeong J. Cha, Mack H. Wu, Sarah Y. Yuan
Journal of Cell Science 2014 127: 1840-1853; doi: 10.1242/jcs.144550
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Research Article
Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells
Richard S. Beard, Jr, Ricci J. Haines, Kevin Y. Wu, Jason J. Reynolds, Stephanie M. Davis, John E. Elliott, Nikolay L. Malinin, Victor Chatterjee, Byeong J. Cha, Mack H. Wu, Sarah Y. Yuan
Journal of Cell Science 2014 127: 1840-1853; doi: 10.1242/jcs.144550

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & tables
  • Supp info
  • Info & metrics
  • PDF + SI
  • PDF

Related articles

Cited by...

More in this TOC section

  • Calcium elevations disrupt interactions between intraflagellar transport and the flagella membrane in Chlamydomonas
  • SFPQ regulates the accumulation of RNA foci and dipeptide repeat proteins from the expanded repeat mutation in C9orf72
  • EFA6A, an exchange factor for Arf6, regulates early steps in ciliogenesis
Show more RESEARCH ARTICLE

Similar articles

Other journals from The Company of Biologists

Development

Journal of Experimental Biology

Disease Models & Mechanisms

Biology Open

Advertisement

2020 at The Company of Biologists

Despite the challenges of 2020, we were able to bring a number of long-term projects and new ventures to fruition. While we look forward to a new year, join us as we reflect on the triumphs of the last 12 months.


Mole – The Corona Files

"This is not going to go away, 'like a miracle.' We have to do magic. And I know we can."

Mole continues to offer his wise words to researchers on how to manage during the COVID-19 pandemic.


Cell scientist to watch – Christine Faulkner

In an interview, Christine Faulkner talks about where her interest in plant science began, how she found the transition between Australia and the UK, and shares her thoughts on virtual conferences.


Read & Publish participation extends worldwide

“The clear advantages are rapid and efficient exposure and easy access to my article around the world. I believe it is great to have this publishing option in fast-growing fields in biomedical research.”

Dr Jaceques Behmoaras (Imperial College London) shares his experience of publishing Open Access as part of our growing Read & Publish initiative. We now have over 60 institutions in 12 countries taking part – find out more and view our full list of participating institutions.


JCS and COVID-19

For more information on measures Journal of Cell Science is taking to support the community during the COVID-19 pandemic, please see here.

If you have any questions or concerns, please do not hestiate to contact the Editorial Office.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Special issues
  • Subject collections
  • Interviews
  • Sign up for alerts

About us

  • About Journal of Cell Science
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Journal Meetings
  • Workshops
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Fast-track manuscripts
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • JCS Prize
  • Manuscript transfer network
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Sign up for alerts

Contacts

  • Contact JCS
  • Subscriptions
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2021   The Company of Biologists Ltd   Registered Charity 277992